HK97593A - Tricyclic compounds - Google Patents

Tricyclic compounds Download PDF

Info

Publication number
HK97593A
HK97593A HK975/93A HK97593A HK97593A HK 97593 A HK97593 A HK 97593A HK 975/93 A HK975/93 A HK 975/93A HK 97593 A HK97593 A HK 97593A HK 97593 A HK97593 A HK 97593A
Authority
HK
Hong Kong
Prior art keywords
compound
formula
dihydrodibenz
oxepin
propylidene
Prior art date
Application number
HK975/93A
Other languages
English (en)
French (fr)
Inventor
William O. Jr. Lever
Harry Jefferson Leighton
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10583945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK97593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of HK97593A publication Critical patent/HK97593A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Claims (10)

1. Verbindung der Formel (I) oder Salz, Ester oder Amid dieser Verbindung, worin
R1 CH2-0- oder-O-CH2- bedeutet,
R2 und R3 gleich oder verschieden sind und jeweils Wasserstoff oder eine C1-4-Alkylgruppe bedeuten oder zusammengenommen mit dem Stickstoffatom einen Stickstoff enthaltenden heterocyclischen Ring mit 4 bis 6 Ringgliedern umfassen,
R4 eine Einfachbindung oder eine zweiwertige, aliphatische C1-7-Kohlenwasserstoff-Gruppe ist und mit dem aromatischen Ringsystem an den Positionen 2, 3, 8 oder 9 verbunden sein kann, und n 0 bis 3 ist.
2. Verbindung der Formel (I) wie in Anspruch 1 definiert, worin Ri -CH20- oder -OCH2- bedeutet,
R2 und R3 gleich oder verschieden sind und jeweils eine C1-4-Alkylgruppe, vorzugsweise Methyl, bedeuten,
R4 eine Einfachbindung oder eine zweiwertige, aliphatische C1-7-Kohlenwasserstoff-Gruppe ist und mit dem aromatischen Ring an den Positionen 2, 3, 8 oder 9, vorzugsweise an der Position 2, verbunden sein kann, und
n 0 bis 3 ist, sowie deren Salze, Amide und Ester.
3. Verbindung der Formel (I) wie in Anspruch 1 definiert, worin Ri -CH20- bedeutet,
R2 und R3 gleich oder verschieden sind und jeweils für einen C1-4-Alkylrest, vorzugsweise Methyl, stehen,
R4 eine Einfachbindung oder eine zweiwertige, aliphatische C1-7-Kohlenwasserstoff-Gruppe ist und mit dem aromatischen Ring an den Positionen 2, 3, 8 oder 9, vorzugsweise an der Position 2, verbunden sein kann, und
n 0 bis 3 ist,
und deren Salze, Ester und Amide.
4. Verbindung der Formel (11) oder Salz, Ester oder Amid, worin
R1 -CH2-O- oder -O-CH2 bedeutet, und
R5 eine Einfachbindung oder die Gruppe -CH=CH bedeutet, die an das aromatische Ringsystem an den Positionen 2, 3, 8 oder 9 gebunden ist.
5. Verbindung, ausgewählt unter folgenden Verbindungen:
(Z)-11-(3-(Dimethylamino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-2-carbonsäure
(E)-11-(3-(Dimethylamino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-2-carbonsäure
(E)-11-(3-(Dimethylamino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-3-carbonsäure (Z)-11-(3-(Dimethy)amino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-3-carbonsäure
(E)-11-(3-(Dimethylamino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-8-carbonsäure (Z)-11-(3-(Dimethylamino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-8-carbonsäure
(E)-11-(3-(Dimethylamino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-9-carbonsäure (Z)-11-(3-(Dimethy)amino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-9-carbonsäure
(E)-11-(3-(Dimethylamino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-2-acrylsäure (Z)-11-(3-(Dimethy)amino)propyliden)-6,11-dihydrodibenz[b,e]oxepin-2-acrylsäure.
6. Pharmazeutische Zusammensetzung, umfassend eine Verbindung der Formel (I) wie in Anspruch 1 definiert in Abmischung mit einem pharmazeutisch annehmbaren Träger.
7. Verbindung der Formel (I) wie in Anspruch 1 definiert zur Verwendung in der Medizin.
8. Verbindung der Formel (I) wie in Anspruch 1 definiert zur Herstellung eines Arzneimittels für die Kontrolle von Allergie.
9. Verbindung der Formel (I) wie in Anspruch 1 definiert zur Herstellung eines Arzneimittels zur Verminderung der nachteiligen Wirkungen von Histamin, zur Kontrolle oder Linderung der Wirkungen eines asthmatischen Zustandes oder zur Kontrolle von Bronchokonstriktionen oder Bronchospasmen, wie sie für allergisches Asthma charakteristisch sind.
10. Verfahren zur Herstellung einer Verbindung der Formel (I) wie in Anspruch 1 definiert, wobei das Verfahren umfaßt:
(a) die Reaktion einer Verbindung der Formel (III) worin Ri und R4 die in Anspruch 1 definierte Bedeutung haben, mit einem geeigneten Wittig-Reagenz oder mit einem geeigneten Grignard-Reagenz und nachfolgende Dehydratation, oder
(b) die Hydrolyse einer Verbindung der Formel (V)worin X R4CN bedeutet und Ri, R2, R3, R4 und n die in Anspruch 1 definierte Bedeutung haben,
(c) wenn es erforderlich ist, eine Verbindung der Formel (I) herzustellen, worin R4 eine Einfachbindung ist, eine Carboxylierungsreaktion an einer Verbindung der Formel (V) wie oben angegeben, worin R1 bis R3 und n die in Patentanspruch 1 definierte Bedeutung haben und X ein Wasserstoff- oder ein Halogenatom ist, oder
(d) wenn es erforderlich ist, eine Verbindung der Formel (I) herzustellen, worin R4 eine andere Bedeutung als die einer Einfachbindung hat, die Reaktion einer Verbindung der Formel (V) wie oben angegeben, worin X ein Halogenatom ist und R1 bis R3 und n die in Anspruch 1 definierte Bedeutung haben, mit einer Verbindung CH2=CHR6COR7, worin R6 für einen zweiwertigen aliphatischen C1-5-Kohlenwasserstoff-Rest und R7 für eine Schutzgruppe steht, und danach Entfernung der Schutzgruppe, wenn erforderlich, und
(e) danach Umwandeln einer Verbindung der Formel (I) in eine andere Verbindung der Formel (I), sofern gewünscht.
HK975/93A 1985-08-17 1993-09-16 Tricyclic compounds HK97593A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858520662A GB8520662D0 (en) 1985-08-17 1985-08-17 Tricyclic aromatic compounds

Publications (1)

Publication Number Publication Date
HK97593A true HK97593A (en) 1993-09-24

Family

ID=10583945

Family Applications (1)

Application Number Title Priority Date Filing Date
HK975/93A HK97593A (en) 1985-08-17 1993-09-16 Tricyclic compounds

Country Status (13)

Country Link
US (1) US4871865A (de)
EP (3) EP0351887B1 (de)
JP (2) JPH0739346B2 (de)
AT (3) ATE97401T1 (de)
DE (3) DE3689311T2 (de)
ES (1) ES2001519A6 (de)
GB (1) GB8520662D0 (de)
GR (1) GR862137B (de)
HK (1) HK97593A (de)
HU (1) HU201520B (de)
IL (1) IL79729A (de)
PT (1) PT83202B (de)
SG (1) SG38393G (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
JPH07116174B2 (ja) * 1987-02-27 1995-12-13 協和醗酵工業株式会社 ジベンズ〔ｂ，ｅ〕オキセピン誘導体
AU605501B2 (en) * 1987-08-25 1991-01-17 Kyowa Hakko Kirin Co., Ltd. Dibenz(b,e)oxepin derivative and antiallergic agent
US4882351A (en) * 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5208238A (en) * 1989-06-19 1993-05-04 Burroughs Wellcome Company Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
IL94768A (en) * 1989-06-19 1995-08-31 Wellcome Found Use of aryl-substituted amine derivatives in the preparation of pharmaceutical compositions
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914040D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
EP0522460A3 (en) * 1991-07-09 1993-03-24 Sumitomo Electric Industries, Ltd. Semiconductor device testing apparatus
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US5899727A (en) 1996-05-02 1999-05-04 Advanced Micro Devices, Inc. Method of making a semiconductor isolation region bounded by a trench and covered with an oxide to improve planarization
DE19848200A1 (de) * 1998-10-20 2000-04-27 Basf Ag Verfahren zur Trocknung von Phenoxymethylbenzoesäuren
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
EP1187617B1 (de) 1999-06-18 2004-03-03 Alcon Manufacturing Ltd. Methode zur konzentrationsbestimmung einer amphipathischen antihistaminischen verbindung durch bestimmung ihrer oberflächen aktivitäts einstufung
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
US6375973B2 (en) 2000-01-25 2002-04-23 Alcon Universal Ltd. Ophthalmic anti-allergy compositions suitable for use with contact lenses
AU5722701A (en) 2000-05-19 2001-12-03 Alcon Universal Ltd Aniline disulfide derivatives for treating allergic diseases
JP2003534274A (ja) 2000-05-19 2003-11-18 アルコン，インコーポレイテッド アレルギー性疾患を処置するための、ベンズアミドジスルフィド誘導体を含む組成物
DK1282599T3 (da) 2000-05-19 2006-07-31 Alcon Inc Disulfidderivater, der er egnede til behandling af allergiske sygdomme
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
KR20050044550A (ko) * 2001-12-05 2005-05-12 알콘, 인코퍼레이티드 비염 치료를 위한 η1 길항제 및 안전한 스테로이드제의용도
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
BRPI0512732A (pt) * 2004-06-28 2008-04-08 Alcon Inc formulações tópicas para tratamento de doenças alérgicas
ES2253996B1 (es) * 2004-07-28 2007-08-16 Urquima, S.A. Procedimiento para la preparacion del acido 11-((z)-3-(dimetilamino)propiliden)-6,11-dihidrodibenz(b,e)oxepinacetico.
MX2007005845A (es) * 2004-11-24 2007-07-04 Alcon Inc Metodo para entregar rocio nasal.
CA2634665A1 (en) 2005-12-22 2007-10-25 Medichem, S.A. Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation
US7950020B2 (en) * 2006-03-16 2011-05-24 Ntt Docomo, Inc. Secure operating system switching
US7687646B2 (en) * 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
PT2114367E (pt) 2007-02-07 2016-02-01 Novartis Ag Formulações de olopatadina para administração nasal tópica
WO2008099900A1 (ja) * 2007-02-16 2008-08-21 Sumitomo Chemical Company, Limited ジベンゾオキセピン化合物の製造方法
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CN101808642B (zh) 2007-09-28 2012-05-02 布里格海姆妇女医院公司 肥大细胞稳定剂治疗肥胖症
CA2718891C (en) * 2008-03-20 2016-10-18 Lek Pharmaceuticals D.D. 2'-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP2666770A1 (de) 2008-07-16 2013-11-27 Crystal Pharma S.A.U Verfahren zur Herstellung von Olopatadin und Zwischenprodukten
WO2010089268A2 (en) * 2009-02-05 2010-08-12 Zach System S.P.A. Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof
IT1397503B1 (it) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint Processo per la preparazione di olopatadina
PL2453872T3 (pl) 2009-07-17 2013-12-31 Alcon Res Ltd Olopatadyna w postaci spreju do donosowego podawania dzieciom
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
WO2014025370A1 (en) 2012-08-10 2014-02-13 Hallstar Innovations Corp. Tricyclic energy quencher compounds for reducing singlet oxygen generation
US9145383B2 (en) 2012-08-10 2015-09-29 Hallstar Innovations Corp. Compositions, apparatus, systems, and methods for resolving electronic excited states
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX367674B (es) 2013-09-13 2019-08-30 Glenmark Specialty Sa Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN105792828A (zh) 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
ES2792682T3 (es) 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (de) 2016-10-07 2020-06-03 Respivant Sciences GmbH Cromolynzusammensetzung zur behandlung von lungenfibrose
HUE071622T2 (hu) 2018-02-23 2025-09-28 Glenmark Specialty Sa Allergiás Rhinitis kezelése gyermekgyógyászati alanyoknál mometazon és olopatadin kombinációjával
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2021094296A1 (en) 2019-11-12 2021-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mast cell stabilizer for the treatment of heart failure with preserved ejection fraction
US20240374555A1 (en) * 2023-04-10 2024-11-14 Magi's Lab Srl Mast Cell Stabilizer with Sodium Cromoglycate-based Inhibitor for Preventing Lipedema Progression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL58901C (de) * 1957-02-07 1947-02-15
DE1232161B (de) * 1961-10-07 1967-01-12 Boehringer & Soehne Gmbh Verfahren zur Herstellung von basisch substituierten Dibenzo-oxepinen und deren Salzen
BE641498A (de) * 1962-03-13
US3401192A (en) * 1962-07-17 1968-09-10 Merck & Co Inc Esters of 5h-dibenzo [a, d] cycloheptene
US3420851A (en) * 1962-12-19 1969-01-07 Pfizer & Co C Novel dibenzoxepines
US3509175A (en) * 1963-10-14 1970-04-28 Pfizer & Co C Recovery of pure cis 11-(3-dimethylaminopropylidene) - 6,11 - dihydrodibenz(b,e)oxepine from admixture with its trans isomer
GB1076612A (en) * 1964-07-24 1967-07-19 Merck & Co Inc Dibenzocycloheptene derivatives
FR2138257B1 (de) * 1971-05-21 1974-08-23 Roussel Uclaf
OA04603A (fr) * 1973-03-02 1980-06-30 Rhone Poulenc Sa Nouveaux dérivés du dibenzo [a,d] cycloheptene, leurs sels et leur préparation.
US3966820A (en) * 1974-07-05 1976-06-29 Syntex (U.S.A.) Inc. 2-Substituted-5-oxo-5H-dibenzo-[A,D]cycloheptenes, the esters and ethers thereof, having pharmaceutical activity, and methods and compositions for the use thereof
JPS5139683A (ja) * 1974-10-02 1976-04-02 Dai Ichi Kogyo Seiyaku Co Ltd Jibenzookisebinjudotaino seizoho
JPS5516590A (en) * 1978-07-21 1980-02-05 Nec Corp Television relay broadcasting equipment
US4282365A (en) * 1978-11-24 1981-08-04 Merck & Co., Inc. Dibenz[b,e]oxepin compounds
US4223013A (en) * 1978-12-29 1980-09-16 Syva Company Amitriptyline conjugates to antigenic proteins and enzymes
US4307245A (en) * 1978-12-29 1981-12-22 Syva Company Amitriptyline conjugates to antigenic proteins and enzymes
JPS56156273A (en) * 1980-03-31 1981-12-02 Dainippon Pharmaceut Co Ltd Acetic derivative
US4412999A (en) * 1982-04-14 1983-11-01 Merck & Co., Inc. Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds
JPS6028972A (ja) * 1983-06-29 1985-02-14 Kyowa Hakko Kogyo Co Ltd ジベンゾ［ｂ，ｅ］オキセピン誘導体

Also Published As

Publication number Publication date
EP0351887B1 (de) 1995-07-26
JPH07165749A (ja) 1995-06-27
EP0214779A1 (de) 1987-03-18
US4871865A (en) 1989-10-03
JPH0739346B2 (ja) 1995-05-01
EP0214779B1 (de) 1990-04-11
DE3670290D1 (de) 1990-05-17
IL79729A (en) 1990-11-05
DE3650357D1 (de) 1995-08-31
SG38393G (en) 1993-06-11
EP0316022A2 (de) 1989-05-17
DE3689311T2 (de) 1994-03-10
EP0351887A1 (de) 1990-01-24
ATE97401T1 (de) 1993-12-15
HUT41761A (en) 1987-05-28
JP2556821B2 (ja) 1996-11-27
DE3689311D1 (de) 1993-12-23
GR862137B (en) 1986-12-30
PT83202B (pt) 1989-03-30
GB8520662D0 (en) 1985-09-25
IL79729A0 (en) 1986-11-30
PT83202A (en) 1986-09-01
EP0316022B1 (de) 1993-11-18
ATE125535T1 (de) 1995-08-15
ATE51867T1 (de) 1990-04-15
HU201520B (en) 1990-11-28
JPS6245557A (ja) 1987-02-27
EP0316022A3 (en) 1989-10-11
ES2001519A6 (es) 1988-06-01
DE3650357T2 (de) 1996-01-04

Similar Documents

Publication Publication Date Title
EP0214779B1 (de) Tricyclische Verbindungen
US4923892A (en) Tricyclic aromatic compounds
US4757074A (en) Piperazinyl benzyl acids having antihistamine activity
US3420851A (en) Novel dibenzoxepines
CA2059127A1 (en) Medicaments useful in cancer therapy and having antihistaminic properties
EP0974583B1 (de) Phenylpiperidin-derivate
EP0085959B1 (de) Aromatische Verbindungen
US5395610A (en) Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US4634699A (en) Branched chain phenothiazine
US4871740A (en) Glycyrrhetic acid derivatives and use thereof
JPH0694464B2 (ja) 三環式化合物およびその中間体
EP0117302B1 (de) Phenothiazin-Derivate
US5191092A (en) Antithrombotic iso- and heterocyclic phenylsulphonamides
US4610995A (en) Certain 1,1-diaryl-propenyl-3-(1-pyrrolidino-2-carboxylic acids, derivatives thereof and their anti-histaminic properties
US4034095A (en) Benzo[5,6]cyclohepta[1,2-c]pyridines
US4564685A (en) Diphenylmethane compounds
PL95266B1 (pl) Sposob wytwarzania nowych pochodnych tiaksantenu
US4024265A (en) Benzo[5,6]cyclohepta[1,2-c]pyridines
US4681878A (en) Fluoropheno-thiazine and pharmaceutical use
US5264458A (en) Antithrombotic iso- and heterocyclic phenylsulphonamides
EP0133534A2 (de) Pyridyl-Verbindungen
GB2145081A (en) Anti-histamine compounds
CS252466B2 (cs) Způsob výroby fenothiazinů
CS252490B2 (cs) Způsob výroby fenothiazinů
CS252488B2 (cs) Způsob výroby fenothiazinů

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060814